Seres Therapeutics (MCRB) EBITDA Margin (2016 - 2026)
Seres Therapeutics' EBITDA Margin was -2799.32% in Q2 2026, up 2822.47 percentage points from the prior quarter.
Powered by 
Analysis
Seres Therapeutics (MCRB) EBITDA Margin (2016 - 2026) Analysis & Trends
On a trailing twelve-month basis, Seres Therapeutics' EBITDA Margin was -4279.61% through Jun 30, 2026; for FY2025, it came in at -11386.31%.
- EBITDA Margin shows a five-year change of -11140.78 percentage points (FY2020 to FY2025).
- In earlier years, EBITDA Margin was -2431.05% in FY2022 (-2390.65 pp) and -40.40% in FY2021 (+205.13 pp).
- The Q2 2026 figure marks the highest quarterly EBITDA Margin since Q2 2023.
- The best year-over-year quarter for EBITDA Margin over five years was Q2 2023 (a gain of 5109.44 percentage points); the worst was Q3 2023 (a drop of 12173.85 percentage points).
- Per Business Quant data, MCRB's EBITDA Margin in the three quarters before Q2 2026 was -5621.79% (Q1 2026), -4206.16% (Q4 2025) and -6106.27% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.82 Bn | 1,105.41 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 617.41 Bn | 535.94 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 501.29 Bn | 474.40 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 368.15 Bn | 322.53 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 297.07 Bn | 261.06 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 260.90 Bn | 234.58 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 236.34 Bn | 191.74 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 191.00 Bn | 165.20 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 169.72 Bn | 116.36 Bn | 10.94 Bn | 39.16% |
| 10 | Seres Therapeutics | 22.57 Mn | -116.27 Mn | - | -2,799.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,799.32% |
| Mar 31, 2026 | -5,621.79% |
| Dec 31, 2025 | -4,206.16% |
| Sep 30, 2025 | -6,106.27% |
| Sep 30, 2023 | -13,712.58% |
| Jun 30, 2023 | 40.48% |
| Mar 31, 2023 | -13,214.75% |
| Dec 31, 2022 | 4.92% |
| Sep 30, 2022 | -1,658.97% |
| Jun 30, 2022 | -5,053.04% |
| Mar 31, 2022 | -3,620.09% |
| Dec 31, 2021 | -633.18% |
| Sep 30, 2021 | 55.26% |
| Jun 30, 2021 | -885.29% |
| Mar 31, 2021 | -589.93% |
| Dec 31, 2020 | -92.05% |
| Sep 30, 2020 | -2,005.58% |
| Jun 30, 2020 | -311.89% |
| Mar 31, 2020 | -218.46% |
| Dec 31, 2019 | -228.18% |
API Access
Seres Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=MCRB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "MCRB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=MCRB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();